WeChat scan to contact the organizer immediately
You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
Interpreting the latest guidelines of global regulations and China's new policies to help biopharma companies to navigate in the changing
Focusing on the development of hot product portfolios -- the next generation of polyclonal antibodies, ADC, nano-antibodies, cell therapy, oncolytic viruses, recombinmant proteins and etc.
Sharing the best practices of global product submissions with multi-centerclinical trials worldwide
Analyzing the latest discoveries and achievements of combined therapy for cancer
Introducing the application of new antibody development platforms to improve R&D efficiency with lower cost
Discussing the optimized bioprocess changing paths and the supervision of post-process changing requirements
Exploring cost-effective biopharma plant design and construction in compliance with GMP requirements
BioCon China is dedicated to establishing a robust idea-exchanging and business-cooperating platform for global regulatory agencies, and worldwide leading biotech companies and Asian biopharmaceutical enterprises. In the previous activities, BioCon China has accumulated 4000+ global industrial participants, 320+ leading products, solution and service providers, and 450+ prominent speakers to join the annual grand events.
Dr. Fan Xiaohu is a well-known expert in the field of Applied Immunology and gene therapy. In 2004, he made a major breakthrough in the basic research of the mechanism of children's blood group incompatibility with heart transplantation. In his original paper published by Nature Medicine, he clarified the mechanism of immune tolerance in the process of children's heart transplantation and demonstrated that infant patients need not consider A before transplantation. BO blood group matched. This achievement breaks the limitation of homogenous organ transplantation and greatly improves the chances of organ transplantation for children with diseases. Returning to China in 2014 and joining Kingsley Group, Kingsley subsidiary Nanjing Legendary Biology was founded in early 2015. Excellent R&D team was established and advanced CAR-T technology platform was independently developed. LCAR-B38M, the first product for the treatment of relapsed and refractory multiple myeloma, achieved international leading results. Since its use in clinical trials in 2016, 74 people have been treated, with a complete response rate of 75%. This product has won a strategic partnership agreement between Johnson & Johnson and Legend to develop the global market for this product. On March 8, 2018, LCAR-B38M products were awarded the first clinical trial approval of CAR-T cell drugs in China, which became an important milestone in the history of cell therapy drugs in China. On May 30, 2018, LCAR-B38M products were also approved by the US FDA for phase Ib/II clinical trials. In 2019, he was eligible for the EU EMA Priority Drug Review. At present, Legendary Biology has the world's largest cell drug research and development team, developed a large number of new CAR-T cancer treatment products and a number of innovative intellectual property platform technology.